Amgen Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Amgen Inc 's ROA in the second quarter of 2026?
Amgen Inc achieved a return on average assets (ROA) of 9.48 % in its second quarter of 2026, this is above AMGN's average return on assets of 9.38%.
Amgen Inc s assets during the 12 months ending in the second quarter of 2026 are valued at $92 billion

ROA has improved compared to 8.64% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 103 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 716, from total ROA ranking in the first quarter of 2026 at 836.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	8.81 %	3.51 %	-1.36 %	-0.82 %	-3.31 %
Y / Y Net Income Change	65.85 %	5.14 %	112.6 %	13.64 %	91.96 %
Net Income (TTM) in million	8,743	7,800	7,711	7,005	6,619
Return On Assets (TTM)	9.48 %	8.64 %	8.62 %	7.8 %	7.35 %
AMGN's Total Ranking	# 716	# 836	# 796	# 857	# 956
Total Assets (TTM) in million	95,639	92,504	90,586	90,141	87,897
Seq. Total Assets Change	3.39 %	2.12 %	0.49 %	2.55 %	-1.64 %
Seq. Net Income Change	30.57 %	36.46 %	-58.55 %	124.58 %	-17.23 %

AMGN's 5 Years Annual ROA >> Back to AMGN Management Effectiveness >> Compare AMGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 15
Sector	# 104
Overall	# 633

Return On Assets Statistics
High	Average	Low
12.98 %	9.38 %	2.49 %
(March 31, 2006)		(Dec 31 2017)

Financial Statements
Amgen Inc 's Assets	$ 95,639 million	AMGN's Balance sheet
Amgen Inc 's Income	$ 2,375 million	Quarterly AMGN's Income Statement
AMGN's Income by Division		See AMGN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-1.36 %	-5.47 %	49.19 %	6.47 %	-2.83 %
Total Assets in million	90,586	91,839	97,154	65,121	61,165
Y / Y Net Income Change	88.53 %	-39.11 %	2.52 %	11.18 %	-18.87 %
Net Income in million	7,711	4,090	6,717	6,552	5,893
Annual Return On Assets	8.51 %	4.45 %	6.91 %	10.06 %	9.63 %

AMGN's 5 Years Annual ROA >> Back to AMGN Management Effectiveness >> Compare AMGN ROA to its Competitors

Comment on AMGN's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 8.51 % compared to prior year, due to annual net income growth of 88.53 % to $7,711.00 million, and due to decline of value in Amgen Inc 's assets by -1.36 % to $90,586.00 million, compared to $90,586.00 a year before.

More Return On Assets Ratios
AMGN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMGN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMGN's Competitors
Subscribers only: Roa for Amgen Inc 's Suppliers
Subscribers only: Return On Assets for AMGN's Customers

You may also want to know
AMGN's Roi	AMGN's Inventory Turnover Ratio	AMGN's Growth Rates	AMGN's Dividend Comparisons
	AMGN's Profitability Ratios	AMGN's Asset Turnover Ratio	AMGN's Dividend Growth
AMGN's Roe	AMGN's Valuation Ratios	AMGN's Financial Strength Ratios	AMGN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %

Date modified: 2026-09-13T23:23:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.